This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove COVID-19 Remove Diabetes Remove Heart Dysfunction
article thumbnail

SGLT-2 Inhibitors Show Mixed Results After Heart Attack

DAIC

APRIL 6, 2024

SGLT-2 inhibitors were initially approved to treat Type 2 diabetes by lowering blood sugar. A heart attack can damage the heart muscle in ways that sometimes lead to heart failure, a condition in which the heart becomes too weak or too stiff to effectively pump blood throughout the body.

Heart Attack 98
Heart Attack Heart attacks Heart Failure Outpatient 98
article thumbnail

EMPACT-MI Trial Outcomes Reported at ACC24: SGLT-2 Inhibitors Show Mixed Results After Heart Attack

DAIC

APRIL 6, 2024

SGLT-2 inhibitors were initially approved to treat Type 2 diabetes by lowering blood sugar. A heart attack can damage the heart muscle in ways that sometimes lead to heart failure, a condition in which the heart becomes too weak or too stiff to effectively pump blood throughout the body.

Heart Attack 81
Heart Attack Heart attacks Heart Failure Outcomes 81
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join thousands of Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024